These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28588651)

  • 1. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.
    Solarić M; Bjartell A; Thyroff-Friesinger U; Meani D
    Ther Adv Urol; 2017 Dec; 9(6):127-136. PubMed ID: 28588651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of two innovative pharmaceutical forms of leuprorelin acetate.
    Geiges G; Schapperer E; Thyroff-Friesinger U; Engert ZV; Gravel P
    Ther Adv Urol; 2013 Feb; 5(1):3-10. PubMed ID: 23372606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
    Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
    Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety profiles of generic and branded leuprorelin acetate microspheres in patients with prostate cancer.
    Zhou Z; Zhou Y; Yan W; Feng T; Liang Z
    Oncol Lett; 2024 Jul; 28(1):319. PubMed ID: 38807677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuprorelin acetate in prostate cancer: a European update.
    Persad R
    Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
    Braeckman J; Michielsen D
    Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of leuprorelin microspheres in prostate cancer.
    Lee M; Browneller R; Wu Z; Jung A; Ratanawong C; Sharifi R
    Adv Drug Deliv Rev; 1997 Oct; 28(1):121-138. PubMed ID: 10837568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
    Schlegel PN;
    J Urol; 2006 Apr; 175(4):1353-8. PubMed ID: 16515997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.